Staphylococcus epidermidis (2018 Data)
Antibiotic |
% Susceptible |
Antibiotic |
% Susceptible |
|
Ampicillin | 0 |
Imipenem | +-* |
|
Azithromycin | +-* |
Levofloxacin | 61 |
|
Aztreonam | - |
Meropenem | +-* |
|
Cefazolin | +/- |
Moxifloxacin | 82
|
|
Cefepime | +/- |
Nitrofurantoin | 99&
|
|
Ceftazidime | +/- |
Oxacillin/Naf | 53 |
|
Ceftriaxone | 52 |
Penicillin | 0 |
|
Cefuroxime | +/- |
Piperacillin | +/-
|
|
Ciprofloxacin | 61 |
Piperacillin/tazo | +-* |
|
Clarithromycin | +-* |
Ticarcillin/Clav | +-* |
|
Clindamycin | 64 |
Tobramycin | +/- |
|
Doxycycline | 83 |
TMP/SMX | 59 |
|
Erythromycin | 37 |
Unasyn/Aug | 53 |
|
Gentamicin | 90 |
Vancomycin | 100 |
|
Number of isolates tested: 436
Comments:
For historical susceptibility data click here
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections